Testing Menu

Covid-19 Screening

COVID-19 

The Minute Molecular Diagnostic test is differentiated from other COVID-19 tests:

  • Asymptomatic Testing - Ability to test for COVID-19 in both symptomatic and asymptomatic patients

  • Qualitative Report -  Positive, negative or invalid

  • Easy to Use - Designed to be CLIA waived for point-of-care

  • Flexible Sample Type - Nasal swab, saliva, nasopharyngeal, UTM/VTM

  • Time to Result - Approximately 15 minutes

  • Accuracy - Lab quality quantitative PCR results

Rapid

Sample-to-result in approximately 15 minutes

Multiplex

One cartridge for multiple test targets (Flu A/B and SARS-CoV-2 in development) collected from a single sample 

Accurate

Quantitative PCR / Central lab accuracy 

Easy to Use

Designed to be CLIA waived for point-of-care

Connectivity

Connect via the cloud

Test Menu In Development

SARS-CoV-2

SARS-CoV-2 test results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.

HIV Viral Load

Measurement of blood plasma HIV-1 RNA concentration ("viral load") using nucleic acid-based molecular diagnostic assays is the standard of care in many areas of the world with access to antiretroviral therapy (ART). Untreated HIV-1 infection is characterized by high-level viral production and CD4 T-cell destruction progressing, despite an often lengthy clinical latency period, to significant net loss of CD4 T cells and AIDS.

CT/NG/TV

DASH CT/NG/TV is a ready-to use test which contains all the necessary reagents for Real-Time PCR assay. The test is designed for the diagnosis of Chlamydia trachomatis, Neisseria gonorrhoeae and/or Trichomonas vaginalis in human urine specimens or vaginal swabs to aid in the assessment of infections caused by these sexually transmitted bacteria.

Flu A, Flu B, CoV-2

Results are for the simultaneous detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus in clinical specimens and is not intended to detect influenza C virus. SARS-CoV-2, influenza A, and influenza B RNA identified by this test are generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. 

HCV

The DASH HCV Genotype II is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the qualitative identification of hepatitis C virus (HCV) genotypes 1-6 in whole blood plasma, or serum from individuals chronically infected with HCV.